Shionogi & Co., Ltd. has obtained domestic manufacturing and marketing approval for the depression treatment drug "Zazvey® Capsules 30mg" in Japan and has launched it in the market as a novel mechanism of action treatment with rapid onset.
4507
Shionogi & Co., Ltd.
2025/12/22
4507
Shionogi & Co., Ltd.
2025/12/22
Shionogi & Co., Ltd. has obtained domestic manufacturing and marketing approval for the depression treatment drug 'Zavege® Capsules 30mg' in Japan and has started market launch as a novel mechanism of action treatment with rapid efficacy.
4507
Shionogi & Co., Ltd.
2025/12/22
Shionogi has acquired the Edaravone business for the treatment of amyotrophic lateral sclerosis and other conditions from Tanabe Pharma, obtaining full global rights. The business is expected to contribute to revenue and profits from fiscal year 2026 onward.